{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:49:05Z","timestamp":1768794545505,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13014-017-0827-7","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T11:40:05Z","timestamp":1498650005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Idelalisib may have the potential to increase radiotherapy side effects"],"prefix":"10.1186","volume":"12","author":[{"given":"Thomas","family":"Gryc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Putz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Goerig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luitpold V.","family":"Distel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"issue":"12","key":"827_CR1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","volume":"100","author":"A Wiestner","year":"2015","unstructured":"Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100(12):1495\u2013507.","journal-title":"Haematologica"},{"issue":"2","key":"827_CR2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.coi.2011.01.001","volume":"23","author":"GV Baracho","year":"2011","unstructured":"Baracho GV, Miletic AV, Omori SA, Cato MH, Rickert RC. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178\u201383.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"827_CR3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol. 2013;23(6):410\u201321.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"827_CR4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649\u201357.","journal-title":"Leukemia"},{"issue":"10","key":"827_CR5","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutre","year":"2015","unstructured":"Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O\u2019Brien SM, Pagel JM, Poleski MH, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779\u201386.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"827_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2307\/3579194","volume":"145","author":"E Gebhart","year":"1996","unstructured":"Gebhart E, Neubauer S, Schmitt G, Birkenhake S, Dunst J. Use of a three-color chromosome in situ suppression technique for the detection of past radiation exposure. Radiat Res. 1996;145(1):47\u201352.","journal-title":"Radiat Res"},{"issue":"5","key":"827_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00066-004-1200-y","volume":"180","author":"U Keller","year":"2004","unstructured":"Keller U, Kuechler A, Liehr T, Muller E, Grabenbauer G, Sauer R, Distel L. Impact of various parameters in detecting chromosomal aberrations by FISH to describe radiosensitivity. Strahlenther Onkol. 2004;180(5):289\u201396.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"827_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0167-8140(97)01932-4","volume":"43","author":"S Neubauer","year":"1997","unstructured":"Neubauer S, Dunst J, Gebhart E. The impact of complex chromosomal rearrangements on the detection of radiosensitivity in cancer patients. Radiother Oncol. 1997;43(2):189\u201395.","journal-title":"Radiother Oncol"},{"issue":"4","key":"827_CR9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00066-016-0951-6","volume":"192","author":"JL Chen","year":"2016","unstructured":"Chen JL, Chen JP, Huang YS, Tsai YC, Tsai MH, Jaw FS, Cheng JC, Kuo SH, Shieh MJ. Radiosensitization in esophageal squamous cell carcinoma: effect of polo-like kinase 1 inhibition. Strahlenther Onkol. 2016;192(4):260\u20138.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"827_CR10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.495","volume":"55","author":"F Jin","year":"2015","unstructured":"Jin F, Robeson M, Zhou H, Moyer C, Wilbert S, Murray B, Ramanathan S. Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol. 2015;55(8):909\u201319.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"827_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128(3):331\u20136.","journal-title":"Blood"},{"issue":"2","key":"827_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140\u201356.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"827_CR13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","volume":"117","author":"BJ Lannutti","year":"2011","unstructured":"Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591\u20134.","journal-title":"Blood"},{"issue":"12","key":"827_CR14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00066-014-0698-x","volume":"190","author":"R Merten","year":"2014","unstructured":"Merten R, Hecht M, Haderlein M, Distel L, Fietkau R, Heinzerling L, Semrau S. Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlenther Onkol. 2014;190(12):1169\u201372.","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"827_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","volume":"190","author":"B Schulze","year":"2014","unstructured":"Schulze B, Meissner M, Wolter M, Rodel C, Weiss C. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol. 2014;190(2):229\u201332.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"827_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00066-016-0950-7","volume":"192","author":"S Stieb","year":"2016","unstructured":"Stieb S, Riesterer O, Brussow C, Pestalozzi B, Guckenberger M, Weiler S. Radiation recall dermatitis induced by sorafenib: a case study and review of the literature. Strahlenther Onkol. 2016;192(5):342\u20138.","journal-title":"Strahlenther Onkol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-017-0827-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T11:40:13Z","timestamp":1498650013000},"score":1,"resource":{"primary":{"URL":"http:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0827-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1186\/s13014-017-0827-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]},"article-number":"109"}}